Clinical Trial

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-23; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06799637
Lead Sponsor Evopoint Biosciences Inc.
Conditions Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
Enrollment 350 participants
Start Date 2023-12-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15